Department of Gastrointestinal Surgery, Fourth Affiliated Hospital, China Medical University, Chongshan East Road 4, Shenyang, 110032, Liaoning, China.
Dig Dis Sci. 2013 Feb;58(2):405-13. doi: 10.1007/s10620-012-2379-x. Epub 2012 Sep 22.
A disintegrin and metallopeptidase with thrombospondin motif type 1 (ADAMTS1) is a recently discovered metalloproteinase with antiangiogenic activity. The function of ADAMTS1 in gastric cancer remains unknown. Therefore, we were interested in examining ADAMTS1 expression in human gastric cancer, as well as its possible correlation with angiogenesis.
The mRNA and protein expression of ADAMTS1, thrombospondin type I (TSP1), and vascular endothelial growth factor (VEGF) was evaluated by RT-PCR and immunohistochemistry, respectively, in 56 paired tumor and normal tissue samples, and corresponding metastatic lymph nodes (n = 42). Microvessel density (MVD) was also evaluated by immunohistochemistry.
ADAMTS1 mRNA and protein levels were significantly lower in primary tumors than in corresponding normal tissues, and were significantly higher in metastatic lymph nodes compared to their matched primary tumors. High ADAMTS1 mRNA and protein expression was found to be significantly associated with lymph node metastasis in primary tumors. There was a negative correlation between ADAMTS1 and VEGF mRNA and protein expression in primary gastric tumors and normal tissues. A negative correlation was also found between ADAMTS1 protein expression and MVD in primary gastric tumors. In contrast, no correlation was detected between ADAMTS1 and TSP1 mRNA and protein expression in primary gastric tumors, normal tissues, and metastatic lymph nodes.
These findings suggest that ADAMTS1 expression is altered in primary gastric cancer and paired lymph node metastasis. In addition, ADAMTS1 has angioinhibitory effects in primary gastric cancer due to its low expression and negative correlation with VEGF and MVD. However, it appears to lose its anti-angiogenic activity in metastatic lymph nodes in gastric cancer.
一种具有血小板反应素基序的解整合素金属蛋白酶 1(ADAMTS1)是一种新发现的具有抗血管生成活性的金属蛋白酶。ADAMTS1 在胃癌中的作用尚不清楚。因此,我们有兴趣研究 ADAMTS1 在人胃癌中的表达及其与血管生成的可能相关性。
通过 RT-PCR 和免疫组织化学分别评估了 56 对肿瘤和正常组织样本以及相应的转移性淋巴结(n=42)中 ADAMTS1、血小板反应素 I(TSP1)和血管内皮生长因子(VEGF)的 mRNA 和蛋白表达。还通过免疫组织化学评估了微血管密度(MVD)。
ADAMTS1 mRNA 和蛋白水平在原发性肿瘤中明显低于相应的正常组织,在转移性淋巴结中明显高于其匹配的原发性肿瘤。高 ADAMTS1 mRNA 和蛋白表达与原发性肿瘤中的淋巴结转移显著相关。在原发性胃癌和正常组织中,ADAMTS1 与 VEGF mRNA 和蛋白表达呈负相关。在原发性胃癌中,ADAMTS1 蛋白表达与 MVD 之间也存在负相关。相反,在原发性胃癌、正常组织和转移性淋巴结中均未检测到 ADAMTS1 与 TSP1 mRNA 和蛋白表达之间的相关性。
这些发现表明 ADAMTS1 在原发性胃癌及其配对的淋巴结转移中表达发生改变。此外,由于 ADAMTS1 表达水平低,与 VEGF 和 MVD 呈负相关,因此在原发性胃癌中具有血管抑制作用。然而,它在胃癌的转移性淋巴结中似乎失去了抗血管生成活性。